APR 09, 2020 4:36 PM PDT

Adjuvant immunotherapy proves effective for colon cancer

Results from a study published in Nature Medicine highlights the benefits of receiving pre-surgery immunotherapy for some types of colon cancer. The NICHE study was carried out by scientists at the Netherlands Cancer Institute and found that 100% of patients in a phase II clinical trial with MSI colon cancer benefited from immunotherapy pre-surgery, while 25% of MSS colon cancer patients saw benefits.

Pre-surgery immunotherapy, also known as neoadjuvant immunotherapy, is meant to keep cancer from metastasizing while also giving the immune system a head-start to recognize tumor variations. Ideally, this allows the immune system a better opportunity to respond once the tumor is removed by surgery.

While the researchers conducting the clinical trials hoped for positive results, they say they were blown away with their findings. 'A good response rate was on the cards in this group', says oncologist and project manager Myriam Chalabi. 'But a 100% rate is unprecedented. You don't dare hope it will be that good.'

Participating in the study were 40 patients with two different colon cancer subtypes: microsatellite-instable (MSI) tumors and microsatellite-stable (MSS) tumors. MSI means that the tumor is very susceptible to mutation; this subtype of colon cancer typically responds well to immunotherapy and the researchers showed that 100% of the patients responded well. MSS, on the other hand, does not typically respond well to immunotherapy; however, the researchers showed that 25% of the group responded well to adjuvant immunotherapy.

The researchers wanted to understand these unexpectedly positive results for MSS. “We looked at all the usual suspects, but they weren't the cause', says Chalabi. “We didn't see the same predictive factors as in melanoma, for instance. But in the end, we did find a new biomarker. If that proves to be predictive in follow-up studies, it could provide a simple way of identifying patients with MSS tumors who could benefit from immunotherapy.”

Photo: Pixabay

The researchers at the Netherlands Cancer Institute had previously shown in past studies that neoadjuvant immunotherapy has similar success outcomes for melanoma; they are simultaneously carrying out investigation on other types of tumors, as well. The researchers plan to continue monitoring the patients already involved in the colon cancer study for a minimum of three more years, in addition to increasing the number of patients involved. 'Only then can the new therapy be considered as a standard treatment', says Chalabi.

Sources: Nature Medicine, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
OCT 27, 2020
Cancer
Increased muscle mass improves outcomes for colorectal cancer surgery
OCT 27, 2020
Increased muscle mass improves outcomes for colorectal cancer surgery
New research published in JAMA Surgery reports a new way to prepare for surgery: sit-ups. According to the findings ...
OCT 30, 2020
Cancer
Fighting mesothelioma with curcumin
OCT 30, 2020
Fighting mesothelioma with curcumin
Research led by investigators at Flinders University in Australia is spearheading new developments in cancer prevention ...
NOV 09, 2020
Cancer
A Prognostic Expression Profile for Osteosarcoma
NOV 09, 2020
A Prognostic Expression Profile for Osteosarcoma
Tireless research goes into every cancer diagnostic tools and new therapy. Many types of cancer have made giant steps fo ...
NOV 23, 2020
Cancer
Where are the geographic hotspots of high mortality rates for women with colorectal cancer?
NOV 23, 2020
Where are the geographic hotspots of high mortality rates for women with colorectal cancer?
A study published in Clinical and Translational Gastroenterology highlights the risk disparities in death rates fro ...
JAN 14, 2021
Clinical & Molecular DX
Tip of the Iceberg: Inaccuracies in Prostate Cancer Diagnostics
JAN 14, 2021
Tip of the Iceberg: Inaccuracies in Prostate Cancer Diagnostics
  Only 10 percent of icebergs are visible on the surface of the water; the remaining 90 percent remains submerged. ...
JAN 14, 2021
Microbiology
Decontaminating the Cancer Microbiome
JAN 14, 2021
Decontaminating the Cancer Microbiome
Valid scientific conclusions require a solid foundation of good data that comes from reliable techniques. Studies that i ...
Loading Comments...